Summit Therapeutics (SMMT) Invested Capital (2019 - 2024)

Summit Therapeutics' (SMMT) quarterly Invested Capital came in at $10.3 million in Q4 2019, up 733.13% on a QoQ basis from $1.2 million in Q4 2019.

Analysis

Summit Therapeutics (SMMT) Invested Capital (2019 - 2024) Analysis & Trends

Summit Therapeutics (SMMT) has 2 years of Invested Capital data on file, last reported at $10.3 million in Q4 2019.

Quarterly Invested Capital changed N/A year-over-year to $10.3 million in Q4 2019, while the trailing twelve-month figure through Sep 2020 was $10.3 million (down 17.26% YoY) and the FY2019 annual result came in at $10.3 million, changed N/A from the prior year.
Invested Capital advanced to $10.3 million in Q4 2019, from $1.2 million in the prior quarter.
In the past five years, Invested Capital ranged from a high of $11.2 million in Q1 2019 to a low of $1.2 million in Q4 2019.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	33.70 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	7.35 Bn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	6.25 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	19.13 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	1.30 Bn
10	Summit Therapeutics	13.67 Bn	12.98 Bn	-	-

Historic Data

Download Data